Purpose of investigation: To report the experience of a single institution in the south of Israel with weekly carboplatin in heavily pretreated patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma. Methods: The hospital records of ten patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma who had 2 nd-line or later chemotherapy with weekly carboplatin between January 2003 and December 2004 were retrospectively reviewed. Weekly carboplatin, at a dose calculated with use of the Hilary Calvert's formula at AUC = 2, was given intravenously in 500 ml dextrose 5% over 30 minutes on day 1 of every seven days. Response was determined using clinical evaluation, radiological reports and CA-125 level. Toxicity was graded using the National Cancer Institute (NCI) criteria. Results: Overall, 155 courses of weekly carboplatin were given. The median number of courses per patient was 14 (range, 2-37) and median duration of treatment was 22.5 (range, 2-40) weeks. Four patients (40%) had complete response lasting for 8-20 (median, 12) weeks, two (20%) had partial response lasting for five and 14 weeks, respectively, one (10%) had stable disease lasting for 23 weeks and three (30%) had progressive disease. Toxicity was mainly hematological with only grade 1-2 hematological toxicity as follows: anemia - four patients (40%), leukopenia - three (30%), neutropenia - three (30%) and thrombocytopenia - two (20%). Conclusion: Weekly carboplatin has considerable activity and low and well tolerated toxicity in heavily pretreated patients with platinum-sensitive recurrent ovarian, peritoneal and fallopian tube carcinoma.
|Number of pages||5|
|Journal||European Journal of Gynaecological Oncology|
|State||Published - 24 Aug 2005|
- Disease response
- Ovarian carcinoma